Teva Pharma And Polpharma Biologics Announce Global Licensing Agreement Granting Teva Exclusive Rights To Commercialize Both Formulations Of Polpharma Biologics’ Proposed Biosimilar To Ocrevus, Upon Regulatory Approval

• Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.
• Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.
• Agreement reflects both companies’ commitment to broadening access to biologic medicines.

TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities.